Fig. 1.

Oral glucose-lowering drug use among patients starting or switching to a basal-bolus insulin regimen with insulin aspart in the A₁chieve study. n = 264 pre-study, n = 194 at baseline and n = 204 at 24 weeks in ≤40 years age-group. n = 2,062 pre-study, n = 1,479 at baseline and n = 1,467 at 24 weeks in >40–65 years age-group. n = 440 pre-study and n = 270 at baseline and 24 weeks in >65 years age-group. OGLD oral glucose-lowering drug